← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vivreon Biosciences, Llc
San Diego, CA
$19,702,937
Total funding
16
Grants
Funding over time
peak $4.1M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,702,937 · 16
By mechanism
R44$15,129,522 · 6
R43$2,577,030 · 9
SB1$1,996,385 · 1
Investigators at Vivreon Biosciences, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,996,385
SB1 · FY2025 · AG
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder$1,401,740
R44 · FY2024 · DA
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$1,371,030
R44 · FY2022 · CA
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,276,596
R44 · FY2022 · AG
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,250,000
R44 · FY2019 · AG
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,249,999
R44 · FY2020 · AG
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$1,223,378
R44 · FY2023 · AG
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder$1,097,854
R44 · FY2025 · DA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$1,004,278
R44 · FY2019 · CA
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis$999,997
R44 · FY2024 · AI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis$999,997
R44 · FY2025 · AI
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$746,325
R44 · FY2017 · AG
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$745,976
R44 · FY2018 · AG
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy$502,010
R44 · FY2024 · CA
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma$352,030
R43 · FY2023 · HL
Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder$349,967
R43 · FY2020 · DA
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder$319,991
R44 · FY2023 · DA
Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies$306,872
R43 · FY2024 · AR
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis$299,989
R43 · FY2022 · AI
Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease$270,902
R43 · FY2019 · AG